Poster-Disease-modifying Therapy
October 25, 2021
Safety of Eculizumab in Nmosd and MG Analysis of the Phase 3 Studies Prevent and Regain and Their Extensions
Background: Aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD) and acetylcholine receptor...
Poster-Disease-modifying Therapy
October 25, 2021
Is There Wearing Off with Ocrelizumab? Preliminary Results of Symptom Burden on Ocrelizumab, a Longitudinal Study (SymBOLS).
Background: Ocrelizumab (OCR), a humanized, anti-CD20 antibody therapy approved for multiple sclerosis (MS), is given at 6-month intervals....
Poster-Disease-modifying Therapy
October 25, 2021
Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis Is Maintained in a Long-Term Open-Label Extension of a Phase II Study
Background: In a 48-week Phase II study NCT02975349, in patients with relapsing multiple sclerosis, evobrutinib was generally...
Poster-Disease-modifying Therapy
October 25, 2021
Characteristics and Outcomes By Employment and Education Status for Patients Treated with Peginterferon Beta-1a or Intramuscular Interferon Beta-1a
Background: Although socioeconomic disparities that lead to differences in multiple sclerosis (MS) outcomes have been identified, specific...
Poster-Disease-modifying Therapy
October 25, 2021
Adherence and Persistence to Injectable Disease-Modifying Therapies Among Patients with Multiple Sclerosis Enrolled in US Commercial Plans
Background: In patients with multiple sclerosis (MS), adherence and persistence to disease-modifying therapies (DMTs) are important to...
Poster-Disease-modifying Therapy
October 25, 2021
Treatment Persistence, Safety, Tolerability, and Effectiveness of Diroximel Fumarate in the Real-World: Design of the Phase 4 ExperienceUS Study
Background: Diroximel fumarate (DRF) is an oral fumarate approved in the United States (US) for relapsing multiple sclerosis (MS). DRF...
Poster-Disease-modifying Therapy
October 25, 2021
Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections and COVID-19
Background: Several integrated analyses have reported on the safety of cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years...
Poster-Disease-modifying Therapy
October 25, 2021
COVID-19 Prevention Behaviors and PCR Testing Among MS Patients Treated with Different Dmts: Survey Data from MS Paths
Background: Emerging data from people with multiple sclerosis (PwMS) suggest that some disease-modifying therapies (DMTs) may impact the...
Poster-Disease-modifying Therapy
October 25, 2021
Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from Prevent
Background: In PREVENT, eculizumab was associated with a significant reduction in relapse risk versus placebo and was well tolerated. In...
Poster-Disease-modifying Therapy
October 25, 2021
Real-World Safety and Effectiveness of Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients: Interim Results from Esteem
Background: Dimethyl fumarate (DMF) demonstrated strong efficacy and a favorable benefitrisk profile in patients with relapsing-remitting...